Literature DB >> 23604187

The German evidence-based guidelines for Hodgkin's lymphoma. Aspects for radiation oncologists.

H T Eich1, J Kriz, H Schmidberger, B Böll, B Klimm, M Rancea, R-P Müller, A Engert.   

Abstract

This report reviews aspects of the German evidence-based guidelines for Hodgkin's lymphoma relevant to radiation oncologists. Stage-adapted treatment is discussed with the focus on radiotherapy. Up-to-date literature citations provide an overview of current recommendations.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23604187     DOI： 10.1007/s00066-013-0331-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


  28 in total

1.  Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?

Authors:  K Spaepen; S Stroobants; P Dupont; J Thomas; P Vandenberghe; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

2.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Authors:  Evert M Noordijk; Patrice Carde; Noëlle Dupouy; Anton Hagenbeek; Augustinus D G Krol; Johanna C Kluin-Nelemans; Umberto Tirelli; Mathieu Monconduit; José Thomas; Houchingue Eghbali; Berthe M P Aleman; Jacques Bosq; Marjeta Vovk; Tom A M Verschueren; Anne-Marie Pény; Théodore Girinsky; John M M Raemaekers; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Authors:  Hans Theodor Eich; Volker Diehl; Helen Görgen; Thomas Pabst; Jana Markova; Jürgen Debus; Anthony Ho; Bernd Dörken; Andreas Rank; Anca-Ligia Grosu; Thomas Wiegel; Johann Hinrich Karstens; Richard Greil; Normann Willich; Heinz Schmidberger; Hartmut Döhner; Peter Borchmann; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Andreas Engert
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

5.  Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.

Authors:  Berthe M P Aleman; John M M Raemaekers; Radka Tomiŝiĉ; Margreet H A Baaijens; Roberto Bortolus; Marnix L M Lybeert; Richard W M van der Maazen; Théodore Girinsky; Geertrui Demeestere; Pieternella Lugtenburg; Yolande Lievens; Daphne de Jong; Antonella Pinna; Michel Henry-Amar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-09       Impact factor: 7.038

6.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Authors:  Christophe Fermé; Houchingue Eghbali; Jacobus H Meerwaldt; Chantal Rieux; Jacques Bosq; Françoise Berger; Théodore Girinsky; Pauline Brice; Mars B van't Veer; Jan A Walewski; Pierre Lederlin; Umberto Tirelli; Patrice Carde; Eric Van den Neste; Emmanuel Gyan; Mathieu Monconduit; Marine Diviné; John M M Raemaekers; Gilles Salles; Evert M Noordijk; Geert-Jan Creemers; Jean Gabarre; Anton Hagenbeek; Oumédaly Reman; Michel Blanc; José Thomas; Brigitte Vié; Johanna C Kluin-Nelemans; Fernando Viseu; Joke W Baars; Philip Poortmans; Pieternella J Lugtenburg; Christian Carrie; Jérôme Jaubert; Michel Henry-Amar
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

7.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

8.  Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

Authors:  D J Sher; P M Mauch; A Van Den Abbeele; A S LaCasce; J Czerminski; A K Ng
Journal:  Ann Oncol       Date:  2009-06-18       Impact factor: 32.976

9.  Involved-field radiotherapy for advanced Hodgkin's lymphoma.

Authors:  Berthe M P Aleman; John M M Raemaekers; Umberto Tirelli; Roberto Bortolus; Mars B van 't Veer; Marnix L M Lybeert; Jo J Keuning; Patrice Carde; Théodore Girinsky; Richard W M van der Maazen; Radka Tomsic; Marjeta Vovk; Achilles van Hoof; Geertrui Demeestere; Pieternella J Lugtenburg; José Thomas; Wilfried Schroyens; Koenraad De Boeck; Johanna W Baars; Johanna C Kluin-Nelemans; Christian Carrie; Malek Aoudjhane; Dominique Bron; Houchingue Eghbali; Wilma G J M Smit; Jacobus H Meerwaldt; Anton Hagenbeek; Antonella Pinna; Michel Henry-Amar
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

10.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Authors:  Andreas Engert; Jeremy Franklin; Hans Theodor Eich; Corinne Brillant; Susanne Sehlen; Claudio Cartoni; Richard Herrmann; Michael Pfreundschuh; Markus Sieber; Hans Tesch; Astrid Franke; Peter Koch; Maike de Wit; Ursula Paulus; Dirk Hasenclever; Markus Loeffler; Rolf-Peter Müller; Hans Konrad Müller-Hermelink; Eckhart Dühmke; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-07-02       Impact factor: 44.544
View more
  5 in total

1.  Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin's lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT.

Authors:  Jan Kriz; Max Spickermann; Philipp Lehrich; Heinz Schmidberger; Gabriele Reinartz; Hans Eich; Uwe Haverkamp
Journal:  Strahlenther Onkol       Date:  2015-04-16       Impact factor: 3.621

2.  Schedule-dependent interaction between vinblastine and irradiation in experimental sarcoma.

Authors:  Maja Cemazar; Tanja Dolinsek; Tina Kosjek; Bostjan Markelc; Gregor Sersa; Veronika Kloboves; Primoz Strojan
Journal:  Strahlenther Onkol       Date:  2014-03-11       Impact factor: 3.621

3.  Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group.

Authors:  C Baues; R Semrau; U S Gaipl; P J Bröckelmann; J Rosenbrock; A Engert; S Marnitz
Journal:  Strahlenther Onkol       Date:  2016-10-04       Impact factor: 3.621

Review 4.  Radiation-induced camptocormia and dropped head syndrome: Review and case report of radiation-induced movement disorders.

Authors:  Clemens Seidel; Thomas Kuhnt; Rolf-Dieter Kortmann; Kathrin Hering
Journal:  Strahlenther Onkol       Date:  2015-06-14       Impact factor: 3.621

Review 5.  Primary EBV-positive Hodgkin's lymphoma of the CNS under azathioprine treatment: case report and review of the literature.

Authors:  Christoph Henkenberens; Anke Franzke; Peter Raab; Ilske Oschlies; Wolfram Klapper; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2014-05-14       Impact factor: 3.621
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.